The CRISPR Screening Facility at the University of North Carolina (UNC) is transforming drug discovery with its advanced gene-editing technology. By allowing researchers to screen the entire human genome, the facility is particularly addressing the challenge of drug resistance in cancer, which accounts for 90% of cancer-related deaths. Researchers Dr. Jose Martinez and Daniel Dominguez from the Lineberger Comprehensive Cancer Center utilized the facility to identify potential targets that could restore chemotherapy sensitivity in Acute Myeloid Leukemia (AML) cells. The facility's director, Nate Hathaway, emphasizes the unbiased approach CRISPR provides, enabling the examination of 20,000 human genes simultaneously. The facility collaborates with both academic and biopharmaceutical entities, offering services that include screen design, experimental work, and detailed analysis. Its unique turn-key expertise is especially beneficial for labs lacking CRISPR experience, while its advanced robotics facilitate high-throughput screenings, allowing for more precise research into various pathways.